TISAGENLECLEUCEL
CCTL019G2201J
Phase 2 small_molecule active
Quick answer
TISAGENLECLEUCEL for High-risk B-cell acute lymphoblastic leukemia is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- High-risk B-cell acute lymphoblastic leukemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active